Volume : 2, Issue : 9, SEP 2016

DETERMINATION OF PREGNANCY OUTCOME IN WOMEN WITH THROMBOPHILIA MUTANAT GENES

Tannaz Sohrabi, Simin Tagavy, Morteza jabarpor Bonyady, Abbasali Dehgani

Abstract

Background and aim: Thrombophilia mutations in pregnancy is not a very common condition, thrombophilia may cause seriuse problems in pregnancies. Hereditary thrombophilia, such as mutations of factor V Leiden, prothrombin G20210A and MTHFR genes, predisposes mothers to missed pregnancies, preeclampsia and abruption, and neonates to preterm deliveries and IUGR. Despite such untoward consequences, there is still dispute on the usefulness of prophylactic treatments. The present study aims to determine the effect of such treatments on maternal and fetal outcomes in mothers with thrombophilia. Methods & Materials: A total of 60 pregnant mothers with mutant thrombophilia genes received LMWH (40 mg/d) plus ASA 80 mg/d). Maternal and neonatal outcomes including abortion, preeclampsia, hypertension without preeclampsia, abruption, preterm delivery and IUGR were documented and compared to those occurred in previous pregnancies.
Results: The mean age patients was 30.05±5.49 years (range: 19-43). Mutations of factor V Leiden, prothrombin G20210A and MTHFR genes were documented in 13.3%, 11.7% and 86.7% of cases, respectively. The rate of normal delivery was 85%. Compared to previous pregnancies, the rate of abortion (p<0.001), preeclampsia (p=0.04) and preterm delivery (p=0.004) decreased significantly after treatment. There were no case with new abruption or IUGR. A significant increase in the rate of hypertension without preeclampsia was documented after treatment, as well.
Conclusion: On the basis of our findings, prophylactic treatment with LMWH plus ASA is effective and safe in reducing maternal and neonatal complication in pregnancies with thrombophilia.

Article : Download PDF

Cite This Article

Article No : 28

Number of Downloads : 995

References

1. Torabi R, Zarei S, Zeraati H, Zarnani AH, Akhondi MM, Hadavi R, et al. Combination
of thrombophilic gene polymorphisms as a cause of increased the risk of recurrent pregnancy
loss. Journal of reproduction & infertility. 2012;13(2):89-94.
2. Adler G, Agnieszka G, Valjevac A, Czerska E, Kiseljakovic E, Salkic NN. Prevalence
of genetic prothrombotic risk factors: 1691G > A FV, 20210G > A PT and 677C > T
MTHFR mutations in the Bosnian population. Annals of human biology.
2015;42(6):576-80.
3. Skrzypczak J, Rajewski M, Wirstlein P, Gozdziewicz T, Breborowicz G, Leszczynska-
Gorzelak B, et al. [Incidence of hereditary thrombophilia in women with pregnancy
loss in multi-center studies in Poland]. Ginekologia polska. 2012;83(5):330-6.
4. Gargano JW, Holzman CB, Senagore PK, Reuss ML, Pathak DR, Friderici KH, et al.
Polymorphisms in thrombophilia and renin-angiotensin system pathways, preterm
delivery, and evidence of placental hemorrhage. American journal of obstetrics and
gynecology. 2009;201(3):317 e1-9.
5. Grandone E, Colaizzo D, Tiscia G, Vergura P, Cappucci F, Greco L, et al. Impact of common
thrombophilias and JAK2 V617F on pregnancy outcomes in unselected Italian
women. Journal of thrombosis and haemostasis : JTH. 2011;9(3):496-501.
6. Coppens M, Folkeringa N, Teune MJ, Hamulyak K, van der Meer J, Prins MH, et al.
Outcome of the subsequent pregnancy after a first loss in women with the factor V
Leiden or prothrombin 20210A mutations. Journal of thrombosis and haemostasis :
JTH. 2007;5(7):1444-8.
7. Parveen F, Shukla A, Agrawal S. Should factor V Leiden mutation and prothrombin
gene polymorphism testing be done in women with recurrent miscarriage from North
India? Archives of gynecology and obstetrics. 2013;287(2):375-81.
8. Canda MT, Demir N, Sezer O. Impact of Factor V Leiden, prothrombin and
methylenetetrahydrofolate reductase gene mutations on infant birth weight in women
with recurrent fetal loss and women with successful pregnancies. Clinical and experimental
obstetrics & gynecology. 2012;39(3):359-61.
9. Kazerooni T, Ghaffarpasand F, Asadi N, Dehkhoda Z, Dehghankhalili M, Kazerooni Y.
Correlation between thrombophilia and recurrent pregnancy loss in patients with
polycystic ovary syndrome: a comparative study. Journal of the Chinese Medical Association
: JCMA. 2013;76(5):282-8.
10. Rodger MA, Paidas M, McLintock C, Middeldorp S, Kahn S, Martinelli I, et al. Inherited
thrombophilia and pregnancy complications revisited. Obstetrics and gynecology.
2008;112(2 Pt 1):320-4.
11. Nurk E, Tell GS, Refsum H, Ueland PM, Vollset SE. Factor V Leiden, pregnancy complications
and adverse outcomes: the Hordaland Homocysteine Study. QJM : monthly
journal of the Association of Physicians. 2006;99(5):289-98.
12. Khalafallah AA, Ibraheem AR, Teo QY, Albarzan AM, Parameswaran R, Hooper E, et
al. Review of Management and Outcomes in Women with Thrombophilia Risk during
Pregnancy at a Single Institution. ISRN obstetrics and gynecology. 2014;2014:381826.
13. Kovac M, Mikovic Z, Mitic G, Djordjevic V, Mandic V, Rakicevic L, et al. Does anticoagulant
therapy improve pregnancy outcome equally, regardless of specific
thrombophilia type? Clinical and applied thrombosis/hemostasis : official journal of
the International Academy of Clinical and Applied Thrombosis/Hemostasis.
2014;20(2):184-9.
14. Mutlu I, Mutlu MF, Biri A, Bulut B, Erdem M, Erdem A. Effects of anticoagulant therapy
on pregnancy outcomes in patients with thrombophilia and previous poor obstetric
history. Blood coagulation & fibrinolysis : an international journal in haemostasis and
thrombosis. 2015;26(3):267-73.
15. Tan WK, Lim SK, Tan LK, Bauptista D. Does low-molecular-weight heparin improve
live birth rates in pregnant women with thrombophilic disorders? A systematic review.
Singapore medical journal. 2012;53(10):659-63.
16. de Jong PG, Quenby S, Bloemenkamp KW, Braams-Lisman BA, de Bruin JP,
Coomarasamy A, et al. ALIFE2 study: low-molecular-weight heparin for women with
recurrent miscarriage and inherited thrombophilia--study protocol for a randomized
controlled trial. Trials. 2015;16:208.
17. Deligiannidis A, Parapanissiou E, Mavridis P, Tabakoudis G, Mavroudi A, Papastavrou
T, et al. Thrombophilia and antithrombotic therapy in women with recurrent spontaneous
abortions. The Journal of reproductive medicine. 2007;52(6):499-502.
18. Grandone E, Tomaiuolo M, Colaizzo D, Ames PR, Margaglione M. Role of
thrombophilia in adverse obstetric outcomes and their prevention using antithrombotic
therapy. Seminars in thrombosis and hemostasis. 2009;35(7):630-43.
19. Mitic G, Novakov Mikic A, Povazan L, Mitreski A, Kopitovic V, Vejnovic T.
Thromboprophylaxis implementation during pregnancy in women with recurrent foetal
losses and thrombophilia. Medicinski pregled. 2011;64(9-10):471-5.
20. Areia AL, Fonseca E, Areia M, Moura P. Low-molecular-weight heparin plus aspirin
versus aspirin alone in pregnant women with hereditary thrombophilia to improve live
birth rate: meta-analysis of randomized controlled trials. Archives of gynecology and
obstetrics. 2016;293(1):81-6.
21. Sergi C, Al Jishi T, Walker M. Factor V Leiden mutation in women with early recurrent
pregnancy loss: a meta-analysis and systematic review of the causal association.
Archives of gynecology and obstetrics. 2014;291(3):671-9.
22. Hoffmann E, Hedlund E, Perin T, Lyndrup J. Is thrombophilia a risk factor for placentamediated
pregnancy complications? Archives of gynecology and obstetrics.
2012;286(3):585-9.
23. Bain E, Wilson A, Tooher R, Gates S, Davis L-J, Middleton P, et al. Prophylaxis for
venous thromboembolic disease in pregnancy and the early postnatal period. 2014.
24. Na. Practice Bulletin No. 138. Obstetrics & Gynecology. 2013;122(3):706-16.
25. Giannubilo SR, Tranquilli AL. Anticoagulant therapy during pregnancy for maternal
and fetal acquired and inherited thrombophilia. Current medicinal chemistry.
2012;19(27):4562-71.
26. Greer IA. Thrombophilia: implications for pregnancy outcome. Thromb Res.
2003;109(2-3):73-81.
27. Ghosh K, Shetty S, Vora S, Salvi V. Successful pregnancy outcome in women with bad
obstetric history and recurrent fetal loss due to thrombophilia: effect of unfractionated
heparin and low-molecular weight heparin. Clinical and applied thrombosis/
hemostasis : official journal of the International Academy of Clinical and Applied
Thrombosis/Hemostasis. 2008;14(2):174-9.
28. Gebhardt GS, Hall DR. Inherited and acquired thrombophilias and poor pregnancy outcome:
should we be treating with heparin? Current opinion in obstetrics & gynecology.
2003;15(6):501-6.
29. Wouters MG, Novakova IR, Steegers EA. [Thrombophilia and the prevention of
thromboembolic complications during pregnancy and the puerperium]. Nederlands
tijdschrift voor geneeskunde. 2003;147(22):1060-6.
30. Kutteh WH. Antiphospholipid antibodies and reproduction. Journal of Reproductive
Immunology. 1997;35(2):151-71.
31. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin
plus heparin in pregnant women with recurrent miscarriage associated with
phospholipid antibodies (or antiphospholipid antibodies). Bmj. 1997;314(7076):253-
7.
32. Bose P, Black S, Kadyrov M, Weissenborn U, Neulen J, Regan L, et al. Heparin and aspirin
attenuate placental apoptosis in vitro: Implications for early pregnancy failure.
American journal of obstetrics and gynecology. 2005;192(1):23-30.
33. Greer IA. Low-molecular-weight heparins for thromboprophylaxis and treatment of
venous thromboembolism in pregnancy: a systematic review of safety and efficacy.
Blood. 2005;106(2):401-7.
34. Bose P, Black S, Kadyrov M, Bartz C, Shlebak A, Regan L, et al. Adverse effects of
lupus anticoagulant positive blood sera on placental viability can be prevented by heparin
in vitro. American journal of obstetrics and gynecology. 2004;191(6):2125-31.
35. Middeldorp S. Low-molecular-weight heparins have no place in recurrent miscarriage:
Debate – For the motion. Thrombosis Research. 2011;127:S105-S9.
36. Middeldorp S. Antithrombotic prophylaxis for women with thrombophilia and pregnancy
complications--No. Journal of thrombosis and haemostasis : JTH.
2003;1(10):2073-4.
37. Di Nisio M, Peters LW, Middeldorp S, Middeldorp S. Aspirin or anticoagulants for the
treatment of recurrent miscarriage in women without antiphospholipid syndrome.
2005.
38. Bujold E, Tapp S, Audibert F, Ferreira E, Forest JC, Rey E, et al. Prevention of adverse
pregnancy outcomes with low-dose ASA in early pregnancy: new perspectives for
future randomized trials. Journal of obstetrics and gynaecology Canada : JOGC = Journal
d'obstetrique et gynecologie du Canada : JOGC. 2011;33(5):480-3.
39. Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet.
1999;353(9160):1258-65.
40. Brenner B, Mandel H, Lanir N, Younis J, Rothbart H, Ohel G, et al. Activated protein C
resistance can be associated with recurrent fetal loss. British journal of haematology.

41. Grandone E, Margaglione M, Colaizzo D, d'Addedda M, Cappucci G, Vecchione G, et
al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses.
Thrombosis and haemostasis. 1997;77(5):822-4.
42. Ridker PM, Miletich JP, Buring JE, Ariyo AA, Price DT, Manson JE, et al. Factor V
Leiden mutation as a risk factor for recurrent pregnancy loss. Annals of internal medicine.
1998;128(12 Pt 1):1000-3.
43. Brenner B. Inherited thrombophilia and fetal loss. Current opinion in hematology.
2000;7(5):290-5.
44. Dizon-Townson DS, Meline L, Nelson LM, Varner M, Ward K. Fetal carriers of the factor
V Leiden mutation are prone to miscarriage and placental infarction. American journal
of obstetrics and gynecology. 1997;177(2):402-5.
45. Meinardi JR, Middeldorp S, de Kam PJ, Koopman MM, van Pampus EC, Hamulyak K,
et al. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Annals of
internal medicine. 1999;130(9):736-9.
46. Younis JS, Brenner B, Ohel G, Tal J, Lanir N, Ben-Ami M. Activated protein C resistance
and factor V Leiden mutation can be associated with first-as well as secondtrimester
recurrent pregnancy loss. American journal of reproductive immunology.
2000;43(1):31-5.
47. Gris JC, Quere I, Monpeyroux F, Mercier E, Ripart-Neveu S, Tailland ML, et al. Casecontrol
study of the frequency of thrombophilic disorders in couples with late foetal
loss and no thrombotic antecedent--the Nimes Obstetricians and Haematologists
Study5 (NOHA5). Thrombosis and haemostasis. 1999;81(6):891-9.
48. Murphy RP, Donoghue C, Nallen RJ, D'Mello M, Regan C, Whitehead AS, et al. Prospective
evaluation of the risk conferred by factor V Leiden and thermolabile
methylenetetrahydrofolate reductase polymorphisms in pregnancy. Arteriosclerosis,
thrombosis, and vascular biology. 2000;20(1):266-70.
49. Rai R, Backos M, Elgaddal S, Shlebak A, Regan L. Factor V Leiden and recurrent miscarriage-
prospective outcome of untreated pregnancies. Human reproduction.
2002;17(2):442-5.
50. Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorp E, Conard J, et al. Increased
fetal loss in women with heritable thrombophilia. Lancet. 1996;348(9032):913-6.
51. Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS. Gestational outcome in
thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thrombosis
and haemostasis. 2000;83(5):693-7.
52. Greer IA. Procoagulant microparticles: new insights and opportunities in pregnancy
loss? Thrombosis and haemostasis. 2001;85(1):3-4.
53. Rodger MA, Walker MC, Smith GN, Wells PS, Ramsay T, Langlois NJ, et al. Is
thrombophilia associated with placenta-mediated pregnancy complications? A prospective
cohort study. Journal of Thrombosis and Haemostasis. 2014;12(4):469-78.
54. Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal
thrombophilia and adverse pregnancy outcome? A systematic review. European journal
of obstetrics, gynecology, and reproductive biology. 2002;101(1):6-14.